Eli Lilly and Company (LLY)
After hours:
| Previous close | 724.87 |
| Open | 723.48 |
| Bid | 733.01 x 1000 |
| Ask | 733.20 x 1100 |
| Day's range | 721.50 - 737.45 |
| 52-week range | 392.26 - 800.78 |
| Volume | |
| Avg. volume | 3,066,637 |
| Market cap | 697.396B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 126.47 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (0.72%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- PR Newswire
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever
- PR Newswire
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
- PR Newswire
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief. These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
